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Glossary 
A: amyloid , a small peptide involved in Alzheimer’s disease pathology 
AD: Alzheimer’s disease 
AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, a key glutamate receptor that is 
targeted by epilepsy treatments 
Decanoic acid: a medium chain fatty acid of ten carbons 
GBM: glioblastoma multiforme, an aggressive form of brain tumour 
GluA1-4: subunits of AMPA receptors 
Ketones: D-β-hydroxybutyrate (BHB) and acetoacetate (ACA) 
Ketogenic: generating ketones 
MCT: medium-chain triglyceride  
Medium chain fatty acids: a fatty acid of 6-12 carbons in length, often derived from MCT 
Octanoic acid: a medium chain fatty acid of eight carbons 
PPAR: peroxisomal proliferator-activated receptor gamma 
PTZ: pentelenetetrazol an epileptogenic compound use to generate seizures 
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Abstract 
 
The ketogenic diet has been used for almost 100 years as a non-pharmacological treatment for refractory 
epilepsy; the generation of ketones was proposed to be a key mechanism by providing neurons with an energy 
source that is more efficient than glucose, resulting in beneficial downstream metabolic changes. However, in 
vitro and in vivo studies have challenged the central role of ketones as medium chain fatty acids, which are part 
of a commonly used ketogenic diet, the medium chain triglyceride (MCT) ketogenic diet, have been 
demonstrated to directly inhibit AMPA receptors (key excitatory neurotransmitter receptors), and to change cell 
energetics through mitochondrial biogenesis. Through these mechanisms, medium chain fatty acids are likely to 
block seizure onset and raise seizure threshold, These mechanisms may also play roles in the  ketogenic diet’s 
potential in other therapeutic areas, such as reducing neurodegeneration in Alzheimer’s disease, proliferation and 
spread of cancer, and insulin resistance in type 2 diabetes. Analyzing medium chain fatty acids in future 
ketogenic diet studies will provide further insights into their importance in other forms of the ketogenic diet. 
Moreover, the results of these studies may facilitate the development of new pharmacological and dietary 
therapies. 
 
Introduction 
The ketogenic diet, a high-fat, low-carbohydrate diet, was developed nearly one century ago as a treatment for  
epilepsy to mimic the metabolic profile of fasting by reducing blood glucose and increasing ketone levels, as 
starvation had long been observed to reduce the frequency of seizures. In the 1920’s and 1930’s, the ketogenic 
diet became an established treatment for epilepsy1, but rapidly lost favor following the development of phenytoin 
and the subsequent growth in antiepileptic drug development. However, there was a resurgence of interest in the 
diet in the 1990’s for drug-resistant epilepsy in children in whom it is increasingly being used. Despite its long 
and burgeoning use, the mechanisms underlying its efficacy in epilepsy have remained unclear. Recent advances, 
however, have resulted in a paradigm shift in our understanding of the putative mechanisms underlying such 
diets, and have paved the way for novel dietary and drug therapies.   
 
The ketogenic diet exists in two main forms. The “classic” ketogenic diet provides 60-80% of dietary energy 
through long chain fats (comprising 16-20 carbons)2. This diet is particularly stringent (there is a very low 
carbohydrate content) and consequently is difficult to maintain. So an alternative medium-chain triglyceride 
(MCT) ketogenic diet was developed2, where fats are provided though triglycerides comprising ~60% octanoic 
(an eight carbon fatty acid) and ~40% decanoic acid (a ten carbon fatty acid). In contrast to the classic ketogenic 
diet, only about 45% of dietary energy is provided by these medium chain fats (so allowing a larger carbohydrate 
component) 2, and more rapid metabolism of the shorter fatty acid results in more efficient ketone generation.  
 
The MCT ketogenic diet is currently used world-wide to treat drug-resistant epilepsy, mainly in children1, but 
also in adults3,4. In addition, both the classical and MCT ketogenic diets have garnered increased interest as 
potential treatments for other diet-sensitive disorders, including Alzheimer’s disease,5-7 cancer,8-12and 
diabetes,13,14 As with epilepsy,  the main therapeutic mechanism was assumed to occur through the replacement 
of carbohydrates by ketones as an alternative energy source15. However, despite the efficacy of the ketogenic diet 
in epilepsy, several studies have shown a poor correlation between plasma ketone levels and seizure control16, 
and ketones do not acutely block seizure activity in an in vitro model.17 Indeed, one study has shown seizure 
control in the absence of ketosis.18 These observations challenge the view that ketones alone have a role in 
seizure control and raise the question of the roles of other components, in particular, the high fat content. Several 
studies have indicated that medium chain fats provided in the MCT ketogenic diet, can have a direct action on 
seizure activity and mitochondrial function. The aim of this review is to summarize the most recent advances in 
our understanding of the mechanisms of action of the MCT ketogenic diet, in relation to epilepsy and other 
disorders.  
 
Metabolism of the MCT ketogenic diet 
Dietary triglycerides ( the main form of dietary fat in the body) are hydrolyzed in the gut and intestines by lipases 
that preferentially hydrolyze medium-chain over long-chain esters19 (Figure 1). Medium-chain triglycerides are 
hydrolyzed to medium-chain fatty acids  (fatty acids with 6-12 carbons), which are then absorbed directly 
through the gut wall, and transferred to the liver where they are rapidly degraded in first-pass metabolism19. The 
liver metabolises these medium chain fatty acids through β-oxidation, which is mainly directed towards the 
generation of three major ketones, β-hydroxybutyrate, acetoacetate, and acetone (collectively called ‘ketone 
bodies’). These ketones as well as those fats that escape metabolism are distributed through the circulatory 
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system in blood. The brain is thought to be dependent primarily on glucose as an energy source, and secondarily 
on hepatically-derived ketone bodies. However, medium chain fatty acids are able to cross the blood-brain 
barrier20,21, reach brain concentrations that are >50% that of plasma fatty acids20 and provide an alternative 
energy source for astrocytes. Evidence indicates that medium chain fatty acids have direct and differing effects 
on astrocyte energy metabolism. Octanoic acid seems to undergo β-oxidation in astrocytes more easily than does 
decanoic acid, and so more readily produces ketones, whereas decanoic acid preferentially stimulates glycolysis, 
producing lactate22 which neurons are able to use as an energy source. Decanoic acid could promote the proposed 
astrocyte-neuron lactate shuttle, which has been proposed to be the main energy source for neurons; however the 
importance of this shuttle in vivo  has been challenged.23 In addition, neurons are also capable of β-oxidation of 
medium chain fatty acids at low rates, but octanoic acid is preferentially oxidized (over decanoic) suggesting a 
key metabolic role in the regulation of medium chain fat levels.24 
 
The MCT ketogenic diet and epilepsy  
 
Ketones and seizures 
Under normal dietary conditions, ketones (acetoacetate, beta-hydroxybutyrate, and acetone) are found in blood 
plasma at very low levels, but their concentration increases under fasting conditions up to a total of 9 mM/L and 
can be taken up by brain, crossing the blood-brain barrier via monocarboxylate transporters25. Under fasting 
conditions, ketones can provide the energy source for cells, and have been considered the key mechanism of 
action of the ketogenic diet15,26. Patients with mutations of the glucose transporter, GLUT1, which plays a critical 
role in glucose transport from the systemic circulation to the brain, respond well to both classical and MCT 
ketogenic diets because ketones are thought to replace the energy supply normally provided by glucose.27 There 
is evidence that glucose supplementation diminishes the anticonvulsant effects of the ketogenic diet in a mouse 
model of epilepsy, so that both fat administration and carbohydrate restriction in the ketogenic diet may be 
important in seizure control.28 It is also likely that ketone bodies influence amino acid metabolism, either directly 
as substrates or indirectly, resulting in changes to GABA and glutamate concentrations.29 But do ketones have 
any direct effects on synaptic transmission or intrinsic neuronal excitability or can they directly or indirectly 
modify neuronal or network excitability ? Neither β-hydroxybutyrate, nor acetoacetate affect ionotropic 
GABAergic (GABA(A) receptor mediated) or glutamatergic (AMPA and NMDA receptor mediated) currents at 
therapeutically relevant concentrations.30 Acetone and β-hydroxybutyrate only affect GABA(A) receptors and 
glycine receptors at toxic levels (>100 mM).31 Nevertheless, there is a suggestion that ketones can compete with 
chloride at the vesicular glutamate transporter, so decreasing vesicular glutamate content and consequently 
glutamatergic transmission.32 In addition, high concentrations of acetoacetate (10 mM) have been shown to 
inhibit voltage-dependent Ca2+ channels (VDCCs) in pyramidal cells of the hippocampus.33 However, ketones at 
high concentrations (10 mM) have no direct effects on in vitro seizure-like activity induced in ex vivo 
hippocampal slices by applying the GABA(A) receptor antagonist, PTZ17, or exposing them to low external 
magnesium.17 The evidence, therefore, despite a possible effect on glutamatergic transmission does not support a 
direct action of ketones on seizure activity. 
 
Ketones can, however, have indirect effects on neuronal and network excitability, and have anti-seizure effects in 
some in vivo seizure models.34-36 Switching from glucose to ketones results in a hyperpolarization of neurons and 
a reduction in neuronal excitability. One indirect mechanism could be the reduction in ATP production from 
glucose oxidation, opening ATP-sensitive potassium (KATP )channels,37; in particular the ketone -
hydroxybutyrate has been proposed to modify seizures through KATP channels (and GABA(B) receptor signaling) 
in a Drosophila seizure model.38 Other possible indirect mechanisms include inhibition of the mitochondrial 
permeability transition pore, which has been implicated in mitochondrial dysfunction and neuronal death,34,35 and 
inhibition of adenosine kinase so increasing adenosine levels, and activating the inhibitory adenosine A1 
receptors34,35. Moreover, ketones have been implicated in epigenetic effects that could be disease modifying in 
chronic epilepsy, possibly through an action on adenosine metabolism.39,40 Overall, there is mixed evidence that 
ketones can have an effect on seizure activity, and it is most likely that this occurs through indirect metabolic 
effects. 
 
Medium chain fats as a direct mechanism for seizure control  
Research on medium-chain triglycerides within the MCT ketogenic diet has provided important insights into the 
roles for fatty acids in seizure control. The efficacy of decanoic acid in seizure control has been shown in in vitro 
experiments, where seizure-like activity is induced in hippocampal slices with PTZ, or perfusion with artificial 
CSF containing no magnesium.17 Importantly, in these studies, decanoic acid blocked seizure-like activity within 
30 minutes of application, within replenishing (perfusate) conditions and  under conditions (high glucose) in 
which ketone generation is unlikely to occur17. Decanoic acid also reduces seizure thresholds in a range of in vivo 
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animal models of acute seizures including both the 6 Hz test (a model of drug resistant seizures)  and the 
maximal electroshock test (a model of tonic-clonic seizures) although it is not active against PTZ-induced 
seizures (proposed to be a model of absence seizures)17,20. These experiments support a direct role of decanoic 
acid in seizure control.   
 
An important step forward in understanding the role for decanoic acid in seizure control was the discovery that 
decanoic acid can act as a selective antagonist of AMPA receptors (Figure 2), demonstrated by direct inhibition 
of these receptors in vitro.17 AMPA receptors, are composed of four subunits, each containing an amino terminal 
and ligand binding extracellular domain, and three transmembrane domains. These receptors are key components 
in the generation of seizures41, are blocked by micromolar concentrations of decanoic acid.17 The mean 
concentration of decanoic acid in blood plasma from patients with epilepsy that receive the MCT ketogenic diet 
is around 157 µM42. Decanoic acid rapidly and easily crosses the blood brain barrier after ingestion in rodent 
models20. It is therefore likely that, in patients with epilepsy on the MCT ketogenic diet, decanoic acid would 
reach sufficient concentrations in the brain to reduce excitation and thereby provide seizure protection. This 
decanoic acid-dependent AMPA receptor inhibition is likely to be receptor isoform specific, shows enhanced 
inhibition during synaptic activation (when neurons are depolarised), and is non-competitive to glutamate17, and 
thus might provide a strong basis for therapeutic efficacy. Interestingly, direct inhibition of AMPA receptor 
activity has been well established as an effective therapeutic mechanism in focal seizures and generalized tonic-
clonic seizures and a recently licensed antiepileptic drug perampanel acts directly on AMPA receptors but at a 
different site from decanoic acid.43,44 Thus, the effects of decanoic acid seen in in vivo models are therefore likely 
to be a direct result of AMPA receptor inhibition.  
 
Octanoic acid is the more abundant fatty acid in the MCT ketogenic diet supplement, and is found in epileptic 
patient blood plasma at around 310 µM.42 A range of animal studies have investigated its role in seizure control. 
In one series of experiments, acute oral dosing of rodents with increasing levels of octanoic acid increased the 
threshold for induction of myoclonic and clonic convulsions in a rat model.21 Octanoic acid also significantly 
increased the seizure threshold in the 6 Hz seizure model, through an adenosine receptor dependent manner 
under reduced glucose levels.45 However, using the same seizure model, this therapeutic effect was not seen in 
animals that received dietary octanoic acid-containing triglycerides16, when glucose levels were not controlled. 
Octanoic acid has no inhibitory activity at AMPA receptors at concentrations found in patients on the MCT 
ketogenic diet17 suggesting the potential anti-seizure effect is more likely to occur through indirect effects on 
adenosine receptors. However, novel branched octanoic acid derivatives, such as 5-methyloctanoic acid provide 
both in vitro and in vivo seizure control and AMPA receptor inhibition.17,46,47  
 
 
Medium chain fats as an indirect mechanism for seizure control.  
An alternative mechanism for the effect of the MCT ketogenic diet on epilepsy arises from beneficial effects 
upon brain energy metabolism. The diet causes alterations in glycolysis and/or mitochondrial function, where 
increasing ATP availability leads to an increase in seizure threshold.48 Although long-chain fatty acids can 
uncouple mitochondria so potentially decreasing ATP production and lowering seizure threshold (although 
mitochondrial uncoupling can also have a paradoxical neuroprotective effect), medium-chain fatty acids are 
much less likely to have a physiological role as uncouplers.19 Clinical studies into the effects of ketogenic diets in 
mitochondrial disorder patients report marked improvements in seizure control.49,50 This may be partly due an 
action of decanoic acid on the peroxisomal proliferator-activated receptor gamma (PPAR)51,52, resulting in  
enhanced mitochondrial function by stimulating mitochondrial biogenesis and increasing mitochondrial complex 
I activity.51 Decanoic acid is a recognized PPAR agonist and PPAR agonists elicit neuronal mitochondrial 
biogenesis (Figure 3).53-55 Similar results have been shown in an in vivo model, where the dietary treatment of 
rats with decanoic acid-containing triglycerides increased brain mitochondrial function and ATP synthesis 
capacity,16 and one study confirmed a synergistic effect of PPAR agonists with the ketogenic diet in an in vivo 
seizure model.56 This mechanism of increased brain mitochondrial function appears to be specific to decanoic 
acid and unlikely to be shared by octanoic acid, the other major component of the MCT supplement. Octanoic 
acid does not activate PPAR53, nor does it enhance levels of mitochondria in vitro51 and octanoic acid-
containing triglycerides do not enhance mitochondria function in vivo.16 In addition, decanoic acid does not affect 
glycolytic enzymes suggesting limited contribution to its anticonvulsant properties.16 The increased activity of 
decanoic acid in these studies, in comparison to octanoic acid, suggests a role for dietary decanoic acid providing 
seizure control from the MCT ketogenic diet.16,20.  
 
Although the discovery of these direct and indirect mechanisms has yet to be widely adopted, their identification 
is likely to trigger an increasing interest in fatty acids as a therapeutic mechanism of the diet. Monitoring plasma 
5 
fatty acid levels (especially medium chain fatty acids) in clinical studies relating to the MCT diet may provide a 
corollary from this. Further research will be needed to examine the complex interactions in the brain between 
medium chain fatty acids,  ketones and the role of both components in therapeutic function.  
 
The MCT ketogenic diet in other diseases 
In addition to the established role drug resistant epilepsy treatment, the MCT ketogenic diet is increasingly being 
considered as a potential treatment for a range of other indications. 
 
Alzheimer’s disease   
The ketogenic diet might be a potential treatment for Alzheimer’s disease since it may function to combat 
metabolic changes underlying the disease.5,6  Reduced uptake and metabolism of glucose has been strongly 
linked to progressive cognitive and motor degeneration as cells starve due to inefficient glycolysis.7 This 
association has provided a rationale for using the ketogenic diet as a therapeutic treatment, where ketones present 
an alternative energy source15 that replenishes glycolytic and tricarboxylic acid cycle intermediates57. One in 
vitro study has also shown that the direct application of the ketone β-hydroxybutyrate in relevant concentrations 
protects hippocampal neurons from amyloid  (A) toxicity.58 In another study, 20 patients with a diagnosis of 
Alzheimer’s disease or mild cognitive impairment, received a single oral dose of MCT, but only those without 
the ApoE4 allele showed enhanced short-term cognitive performance with a range of tests, indicating that ApoE4 
genotype may influence response to dietary treatments.59 In addition, both classical and MCT ketogenic diets 
improve motor function, but not cognition, in a transgenic mice model of amyloid deposition.60 Three studies 
(including two randomized control trials) have reported that treatment with an MCT diets benefitted only patients 
with mild forms of Alzheimer’s disease but not those that were genetically predisposed with an ApoE4 mutation 
which is strongly associated with an increased risk of developing Alzheimer’s disease.61-63 
 
There is strong evidence that A increases AMPA receptor currents and triggers subunit internalization; this   
directly links glutamate receptor hyperactivity to neurotoxicity and memory loss in Alzheimer’s disease. A has 
been shown to interact with  adrenergic receptors which regulate gene expression and the activity of receptors 
including AMPA-type glutamate receptors via the cAMP/PKA signaling cascade.64,65 Phosphorylation of AMPA 
receptor GluA1 subunits by PKA has been shown to increase channel opening probability which results in 
augmented calcium entry into the cell, leading to neurotoxicity.66 A study67 has shown that the addition of Aβ to 
neuronal cultures causes neurotoxicity by strengthening calcium-dependent AMPA-receptor generated currents. 
This suggests that Aβ induced excitotoxicity could contribute to the widespread neuronal death in Alzheimer’s 
disease. In addition to ketones providing energy to glucose resistant neurons, the MCT ketogenic diet might also 
improve neuronal survival through the inhibition of AMPA receptors by decanoic acid. There is evidence that A 
treatment triggers the internalization of GluA2 subunits, the only AMPA receptor subunit type that confers 
calcium impermeability.68,69 Internalization of GluA2 could therefore further increase total post-synaptic calcium 
influx, which could further increase inflammation and neurotoxicity. It needs to be noted, however, that it has 
been suggested that Aβ-induced internalization of AMPA receptor subunits could be sufficient to reduce LTP 
and therefore be linked to memory loss in Alzheimer’s disease.70 Indeed, patient studies have shown that loss of 
GluA2 precedes pathological marker (tangle) development in the brain.71 This effect would be augmented if the 
remaining postsynaptic subunits were to be blocked by AMPA receptor antagonists. More research is needed to 
determine a role for the MCT ketogenic diet and AMPA receptor antagonists in the treatment of Alzheimer’s 
disease. 
 
Mitochondrial dysfunction has also been implicated in the pathogenesis of Alzheimer’s disease. With a high 
demand for energy, the brain is rendered dependent on mitochondria, leaving it sensitive to aberrant changes in 
mitochondrial function. Structural abnormalities of mitochondria, imbalances in mitochondrial fission and fusion, 
and defective electron transport chain activity have been observed in Alzheimer’s disease models.72 Moreover, 
evidence suggests that Aβ accumulation is associated with toxic effects against mitochondria, including impaired 
energy homeostasis and electron transport chain complex activity, particularly of cytochrome c oxidase72, 
disrupted mitochondrial structure and dynamics73, and increased mitochondrial oxidative stress.72,74 With 
mitochondria intrinsically linked to cell signaling, mitochondrial damage consequentially leads to cell death and 
may potentially be responsible for the synaptic degeneration observed in Alzheimer’s disease. However, very 
few studies have investigated the therapeutic effects of the MCT ketogenic diet in light of mitochondrial 
function, although one in vitro study has reported the attenuation of deleterious Aβ-induced effects on cortical 
neurons treated with coconut oil (containing high levels of MCT), observing increased cell survival and 
improved mitochondrial structure and size.75 Whilst the mechanisms of these observed effects remain unknown, 
there remains a potential for the role of medium chain fatty acids in this context. In particular, decanoic acid, 
which has the ability to improve mitochondrial function51,76 may prove beneficial in the amelioration of Aβ-
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induced mitochondrial damage. In addition, role of decanoic acid as an antioxidant51,77 and as a PPAR 
activator78 may  provide molecular mechanisms underlying the improved mitochondrial function. 
 
Cancer    
Ketogenic diets have gained considerable interest as an adjunctive therapy in the treatment of cancer, with data 
from both different animal models8 and observational patient studies9-12, although evidence for clinical efficacy 
from randomized controlled trials is lacking. Cancer cells are often highly dependent on glucose as a substrate, 
relying on anaerobic glycolysis to provide ATP, known as the Warburg effect79; this dependence on glucose is 
utilized in tumor imaging using positron emission tomographic uptake of fluorodeoxyglucose. The commonly 
accepted mechanism by which the ketogenic diet may aid in cancer therapy is that the lowering of circulating 
glucose, and the inability of tumors to use ketone bodies, results in reduced tumor growth or tumor 
regression.80,81 Whilst this theory remains the most accepted explanation for a mechanism of the ketogenic diet, 
several studies have suggested that the effect on tumor growth may not be solely via a decrease in glucose levels. 
9,12,82 Indeed, many tumors preferentially use glutamine as a substrate rather than glucose but whether a ketogenic 
diet has any effect on such tumors is unknown. 
 
A link between the MCT ketogenic diet, AMPA receptors, and cancer treatment comes from studies 
demonstrating that human glioblastoma cells express increased levels of AMPA receptors83, and inhibition of 
AMPA receptors suppresses migration and proliferation of glioblastoma multiforme cells84 and other cancer 
cells85. Furthermore, the recently licensed AMPA receptor-specific inhibitor Perampanel, which binds at a 
different site to decanoic acid (Figure 2)17, has been shown to be a potentially chemotherapeutically active 
adjuvant in a single case study of glioblastoma multiforme cells treatment.86 These studies thus suggest that 
AMPA receptor inhibition through decanoic acid17 might provide an adjunctive cancer treatment. 
 
 
 
Diabetes  
Diabetes can be broadly split into type 1 diabetes, in which the pancreas does not produce enough insulin due to 
a combination of genetic and environmental factors, and type 2 diabetes in which lifestyle choices including 
obesogenic diets rich in carbohydrates and saturated fats, together with lack of exercise, lead to hyperglycaemia 
and insulin resistance.87 Dietary interventions, including the MCT ketogenic diet have been investigated as new 
therapeutic approaches, mainly in type 2 diabetes mellitus due to its increased incidence. In a number of studies, 
MCT ketogenic diets have been found to reduce serum lipid levels and improve lipid profiles, decrease body fat 
and reduce total body weight in both animals13 and humans14 and to increase energy expenditure.88 MCTs also 
reduce insulin resistance and improve glucose tolerance in animal models and in patients with Type 2 
diabetes.13,89 Although the exact mechanism of these overall effects remains unknown, these studies suggest a 
beneficial role of MCTs in the treatment of type 2 diabetes and associated glucose-sensitive metabolic disorders 
(eg, XX +ref). Ketogenic diets in patients with type 1 diabetes is more limited and the literature consists of case 
reports of patients with type 1 diabetes and poorly controlled epilepsy, or anecdotal reports. A major concern 
about implementation of any ketogenic diet in patients with diabetes, especially type 1, is the potentially life-
threatening complication of diabetic ketoacidosis as a lack of insulin promotes fatty acid oxidation and ketosis.  
 
Mitochondrial dysfunction has also been postulated to play a role in insulin resistance and, consequently, the 
pathology of diabetes. Patients with Type 2 diabetes have been found to exhibit impaired mitochondrial 
activity90, with alterations in function and morphology91, as well as increased reactive oxygen species levels92, 
linked to insulin resistance. Genetic variations and alterations in gene expression of PPARγ coactivator-193, the 
master regulator of mitochondrial biogenesis, have also been proposed to play a role in the pathogenesis of 
diabetes. In light of these findings, a role for decanoic acid as a PPARγ agonist may provide a therapeutic effect 
in treatment of diabetes. Thus, increasing mitochondrial content through decanoic acid treatment, in conjunction 
with improved mitochondrial function and increased antioxidant capacity, could form a vital defence against the 
deleterious effects of mitochondrial dysfunction in diabetes.  
 
Conclusion and future directions 
The MCT ketogenic diet is widely considered to function through the generation of ketones, in the treatment of a 
range of disorders including epilepsy, cancer, Alzheimer’s disease, and diabetes. However, the underlying 
mechanisms of the diet are still largely unknown. The recent discovery of roles for medium chain fats, provided 
in the diet, in the direct inhibition of a key neurotransmitter receptor (the AMPA receptor), and through 
regulating cellular energy through PPAR activation and mitochondrial biosynthesis have provided alternative 
therapeutic mechanisms to explore. Understanding the role of AMPA, PPAR and mitochondrial biosynthesis, in 
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relation to MCT ketogenic diet-responsive disorders may provide new therapeutic targets, and facilitate the 
development of new pharmacological and dietary treatments such as altered fatty acid with MCTs, or chemical 
modification of fats to reduce first-pass metabolism clearance. Since the proposed mechanism of AMPA receptor 
inhibition, PPAR activation and mitochondrial biosynthesis provides a rationale for efficacy in other conditions, 
further clinical studies are necessary to validate the use of the MCT ketogenic diet in treatment in these disorders 
(Table 1). In addition, further clinical studies are necessary to either decrease or mitigate potential adverse effects 
of ketogenic diets, such as the low grade acidosis resulting from elevation in β-hydroxybutyric and acetoacetic 
acids.94 Furthermore, it remains to be elucidated if other ketogenic diets, such as the classical diet, are also 
associated with elevated levels of medium chain fatty acids, and monitoring of these components in clinical 
studies will help to explore these mechanisms. Validation of these and other targets of fats provided in the diet 
may both improve and widen the use of the diet, in both children and adults, for the treatment of epilepsy, cancer, 
Alzheimer’s disease, diabetes, and other disorders. 
 
Search strategy and selection criteria 
We selected references by searching PubMed for manuscripts published in English between Month/Day 2010 
and Sept 18st 2017, using the term “ketogenic diet” or ”medium chain triglyceride” and assorted combinations of 
the following terms: “epilepsy”, “seizures”, “antiepileptic drugs”, “dementia”, “neurodegenerative disease”, 
“Alzheimer’s disease”, “diabetes”, “cancer”, and “tumor”. We examined the reference lists within original 
research and review articles for additional references. We finalised the reference list on the basis of originality 
and relevance to the scope of this Review.  
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Figure 1: Breakdown and circulation of dietary medium chain trigylcerides.   (1) The consumption of MCT 
(containing decanoic acid (ten carbon) and octanoic acid (eight carbon)) as a supplement in the MCT ketogenic 
diet. (2) Medium chain fatty acids (decanoic acid and octanoic acid) are liberated from the triglycerides in the 
intestine, transferred to the liver, where (3) the majority of these medium chain fatty acids are broken down to 
three ketone bodies (BHB, ACA and acetone). (4) Both fatty acids and ketones are transported through the 
circulation to the brain. (5) Transport of fatty acids and ketones across the blood brain barrier leads to neuronal 
exposure as the site of action for the treatment of epilepsy. 
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Figure 2: Schematic representation of the relation between AMPA receptors and decanoic acid. Schematic 
representation of AMPA receptors that occur as heterotetramers. Individual subunits comprise a large extra-
cellular amino (NH2) terminal domain and ligand binding domain (for glutamate), three transmembrane domains 
(M1, M3 and M4) and reentry loop (M2). The proposed site for decanoic acid, on the M3 domain, is distinct to 
that of perampanel at the linker regions (S1-M1 and S2-M4) to the M1 and M4 domains. The carboxy terminal 
(HOOC) resides on the cytoplasmic side of the membrane.  
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Figure 3: Schematic representation of the activation of peroxisome proliferator-activated receptor gamma 
(PPAR) signaling through decanoic acid. Decanoic acid (DA) binds the PPAR to bind target DNA (with the 
retinoid X receptor (RXR) to elevate gene transcription, where enhanced gene expression is thought to trigger 
mitochondrial biogenesis. This effects leads to elevated tricarboxylic acid (TCA) cycle and complex 1 activity, 
and complex 1 activity, resulting in optimal ATP availability.   
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Identifier Study title Intervention(s) Condition/study 
population 
Lead centre Expected date 
of completion* 
NCT03075514 Ketogenic Diets as an Adjuvant Therapy in 
Glioblastoma: A Randomised Pilot Trial 
Modified KD 
vs. MCT KD 
Glioblastoma University of 
Liverpool, UK 
March 2018 
NCT02825745 Use of Betashot in Children and Adults 
With Epilepsy 
MCT based 
emulsion 
Epilepsy National Hospital for 
Neurol. & Neurosurg. 
& Great Ormond 
Street Hospital for 
Children, UK 
December 2017 
NCT02516501 Impact of a Ketogenic Diet Intervention 
During Radiotherapy on Body Composition 
MCT based 
emulsion 
Neoplasms Schweinfurt, Germany June 2018 
NCT02021526 Triheptanoin (C7 Oil), a Food Supplement, 
for Glucose Transporter Type I Deficiency  
Normal diet + 
C7 oil vs. C7 oil 
as part of KD 
Glucose 
Transporter Type 
I Deficiency 
University of Texas 
Southwestern Medical 
Center, USA 
June 2019 
NCT02426047 Medium Chain Triglycerides as an Adjunct 
to the Modified Atkins Diet for Women 
With Catamenial Epilepsy 
Modified Atkins 
diet plus MCT 
based emulsion 
Epilepsy Johns Hopkins 
University, USA 
March 2018 
NCT02912936 A Medium Chain Triglyceride Intervention 
for Patients With Alzheimer Disease 
MCT milk vs. 
olive oil milk 
Alzheimer’s 
Disease 
University of British 
Columbia, Canada 
February 2018 
NCT02679222 Comparing the Ketogenic Effect of 
Coconut Oil and Different MCTs 
Different MCT 
supplements 
Healthy adults Université de 
Sherbrooke, Canada 
December 2016 
NCT02709356 Medium Chain Triglycerides and Brain 
Metabolism in Alzheimer's Disease 
Different MCT 
emulsions 
Alzheimer's 
disease / healthy 
elderly people 
Université de 
Sherbrooke, Canada 
July 2017 
NCT02409927 Effect of MCT Emulsification on 
Ketogenesis in Human Adults 
Different MCT 
preparations 
Healthy adults Université de 
Sherbrooke, Canada 
September 2014 
NCT02551419 Proof of Mechanism of a New Ketogenic 
Supplement Using Dual Tracer PET 
(Positron Emission Tomography) 
MCT milk vs. 
olive oil milk 
Adults with Mild 
Cognitive 
Impairment 
Université de 
Sherbrooke, Canada 
June 2018 
* Final data collection date for primary outcome measure 
Table 1: Current clinical trials using medium-chain triglyceride ketogenic diets. Clinicaltrials.gov was search using the terms ‘medium-
chain’ AND ‘ketogenic’ in October 2017
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